# Market Thesis Research Bundle

Question: Given the White House pricing agreement with nine drugmakers, will at least one other large branded-pharma company announce a broader direct-to-patient or government-linked pricing concession that changes its U.S. rebate, list-price, or launch strategy by year-end 2026?

What this bundle is: a reasoning and monitoring scaffold. It organizes public evidence into observations, claims, uncertainty branches, thresholds, and a watch plan.

What this bundle is not: primary evidence, live market data, trade advice, or a substitute for official, live, or current web sources.

Core tension: Given the White House pricing agreement with nine drugmakers, will at least one other large branded-pharma company announce a broader direct-to-patient or government-linked pricing concession that changes its U.S. rebate, list-price, or launch strategy by year-end 2026?

Current inference to verify: {'state': 'already_true_at_cutoff', 'inference': 'As of the cutoff, the condition appears already satisfied: multiple large branded-pharma companies outside the nine-drugmaker White House announcement had already publicly disclosed qualifying pricing concessions or government-linked access changes.', 'confidence': 0.98, 'basis_source_ids': ['s1', 's2', 's3', 's5', 's7', 's9'], 'verification_note': 'This is a present-state inference from public disclosures, not a forward prediction signal.'} Treat this as a hypothesis that must be refreshed against live official sources, not as a signal.

How to use: read `source_priority.json` first, refresh sources in `live_verification_plan.json`, then use `fact_inference_split.json`, `thresholds.json`, and `watch_schedule.json` to decide what changed. Do not infer buy/sell/hold, position sizing, execution, or asset-price direction from this artifact.